治疗胆汁淤积的新型疗法
Novel Therapies for Managing Cholestasis.
作者信息
Santiago Priscila, Levy Cynthia
机构信息
Department of Medicine University of Miami Miller School of Medicine Miami FL.
Division of Hepatology University of Miami Miller School of Medicine Miami FL.
出版信息
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):95-99. doi: 10.1002/cld.886. eCollection 2020 Mar.
Abstract
http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-3-reading-santiago a video presentation of this article http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-3-interview-levy an interview with the author https://www.wileyhealthlearning.com/Activity/7058605/disclaimerspopup.aspx quertions and earn CME.
摘要
http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-3-reading-santiago 本文的视频展示http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-3-interview-levy 对作者的采访https://www.wileyhealthlearning.com/Activity/7058605/disclaimerspopup.aspx 提问并获得继续医学教育学分。
相似文献
1
Novel Therapies for Managing Cholestasis.治疗胆汁淤积的新型疗法
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):95-99. doi: 10.1002/cld.886. eCollection 2020 Mar.
2
Managing the Symptoms and Complications of Cholestasis.胆汁淤积症状及并发症的管理
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):120-124. doi: 10.1002/cld.901. eCollection 2020 Mar.
3
The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice.胆汁淤积的病理生理学及其与临床实践的相关性。
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):110-114. doi: 10.1002/cld.894. eCollection 2020 Mar.
4
Nutritional Management of Cholestasis.胆汁淤积的营养管理
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):9-12. doi: 10.1002/cld.865. eCollection 2020 Jan.
5
Isolated Elevated Bilirubin.孤立性胆红素升高
Clin Liver Dis (Hoboken). 2020 May 7;15(4):153-156. doi: 10.1002/cld.944. eCollection 2020 Apr.
6
Spotlight on Impactful Research: Long-Term Calcineurin Inhibitor Therapy and Brain Function in Patients After Liver Transplantation.聚焦有影响力的研究：肝移植术后患者长期钙调神经磷酸酶抑制剂治疗与脑功能
Clin Liver Dis (Hoboken). 2020 May 7;15(4):141-143. doi: 10.1002/cld.910. eCollection 2020 Apr.
7
Treating Alcohol Use Disorder in Chronic Liver Disease.治疗慢性肝病中的酒精使用障碍
Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):77-80. doi: 10.1002/cld.881. eCollection 2020 Feb.
8
Spotlight on Impactful Research: Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients With Cirrhosis Undergoing Liver Transplant Evaluation.聚焦重大研究：阿司匹林和他汀类药物在接受肝移植评估的肝硬化患者冠状动脉疾病管理中的应用
Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):69-70. doi: 10.1002/cld.899. eCollection 2020 Feb.
9
Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines.乙型肝炎病毒再激活：临床指南综述
Clin Liver Dis (Hoboken). 2020 May 7;15(4):162-167. doi: 10.1002/cld.883. eCollection 2020 Apr.
10
Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝纤维化评估中非侵入性方法的应用与局限性
Clin Liver Dis (Hoboken). 2020 May 7;15(4):157-161. doi: 10.1002/cld.878. eCollection 2020 Apr.
引用本文的文献
1
Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies.Licraside作为新型强效FXR激动剂用于缓解胆汁淤积：基于结构的药物发现与生物学评价研究
Front Pharmacol. 2023 Jun 15;14:1197856. doi: 10.3389/fphar.2023.1197856. eCollection 2023.
本文引用的文献
1
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.非甾体法尼醇 X 受体激动剂西利福昔（GS-9674）可改善原发性硬化性胆管炎患者的胆汁淤积和肝损伤标志物。
Hepatology. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509. Epub 2019 Mar 10.
2
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.西姆土单抗治疗原发性硬化性胆管炎：2 期研究结果及对疾病自然史的见解。
Hepatology. 2019 Feb;69(2):684-698. doi: 10.1002/hep.30237. Epub 2019 Jan 11.
3
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.原发性胆汁性胆管炎：美国肝病研究协会2018年实践指南
Hepatology. 2019 Jan;69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6.
4
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.塞拉得帕（MBX-8025），一种选择性过氧化物酶体增殖物激活受体 δ 激动剂，用于治疗对熊去氧胆酸应答不足的原发性胆汁性胆管炎患者：一项双盲、随机、安慰剂对照、2 期、概念验证研究。
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.
5
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.熊去氧胆酸可改善原发性硬化性胆管炎的胆汁淤积。
J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.
6
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的安慰剂对照临床试验。
N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.
7
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.全反式维甲酸联合熊去氧胆酸治疗原发性硬化性胆管炎患者：一项人体初步研究。
J Clin Gastroenterol. 2017 Feb;51(2):e11-e16. doi: 10.1097/MCG.0000000000000591.
8
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.初步研究：非诺贝特治疗对熊去氧胆酸应答不完全的原发性胆汁性肝硬化患者。
Aliment Pharmacol Ther. 2011 Jan;33(2):235-42. doi: 10.1111/j.1365-2036.2010.04512.x. Epub 2010 Nov 17.
Zotero 插件